Project Grant K23DA062008
Award Date
4/15/25
Completion Date
3/31/30
Dollars Obligated
$195K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Institute on Drug Abuse (NIDA), through the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $177,170 Project Grant to the University of Massachusetts Medical School (UMass Medical) to assess strategies for implementing Medications for Opioid Use Disorder (MOUD) treatment in Massachusetts jails. The 3-year project, beginning in June 2024, aims to qualitatively evaluate organizational factors related to MOUD implementation, investigate staff perspectives on MOUD, and...
The National Institute on Drug Abuse (NIDA) awarded a $223,715 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington to explore the neurobehavioral effects of concurrent opioid and methamphetamine use disorders. The key objectives are to: 1) Define the behavioral profile of dual opioid-methamphetamine use disorders in a rodent model, comparing polysubstance and mono-substance addiction patterns, and 2) Map neural activation patterns within...
The National Institute on Drug Abuse (NIDA) awarded a $564,326 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Trustees of Columbia University in the City of New York, Health Sciences Division. The project, titled "Leveraging Harmonized Data to Improve External Validity and Efficiency of Clinical Trials for Treating Opioid Use Disorder," aims to develop new statistical methods for combining data from multiple clinical trials to enhance the power...
The National Institute on Drug Abuse (NIDA) awarded a $139,000 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Temple University to investigate the ability of the chemokine receptor antagonist AMD3100 to reduce heroin self-administration and relapse behaviors in animal models. The researchers will examine the role of the chemokine receptor CXCR4 in dopaminergic neurons within the ventral tegmental area in modifying heroin taking behaviors. This work aims to...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
The National Institute on Drug Abuse (NIDA) awarded a $267,696 project grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the University of Massachusetts Lowell to enhance opportunities for addiction research within the Merrimack Valley region. The 5-year project aims to: 1) expand the university's existing undergraduate public health informatics and technology (PHIT) program with a new focus on applying data sciences to drug addiction research; 2) recruit a diverse student body...
This $419,876 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to conduct preclinical trials to evaluate the potential of neuropeptide S (NPS) receptor targeted molecules for mitigating opioid use disorders. The research will investigate whether NPS receptor activation can reduce oxycodone self-administration and motivation to obtain the drug in rodent models. This work seeks to advance the understanding of...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,539,426 Project Grant to Serodopa Therapeutics Inc. The goal of this 24-month grant is to complete the formulation development and preclinical testing required to bring Serodopa's novel naloxone derivative drug product to a point of readiness to file an Investigational New Drug (IND) application with the FDA. This drug product is intended to be an intranasal overdose...
This $483,056 Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the molecular mechanisms linking opioid addiction, circadian rhythms, and sleep disturbances. The primary focus is on understanding the role of the circadian transcription factor NPAS2 and the dopamine D3 receptor in the nucleus accumbens as they relate to fentanyl craving and relapse behaviors in male and female...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $636,344 to Cari Health, Inc. to develop and commercialize a new technology for individualized methadone dosing for the treatment of opioid use disorders (OUDs). The project aims to create a point-of-care device that can rapidly evaluate a patient's methadone metabolism rate using a simple finger prick blood sample. This will enable more...